Episurf Medical reaches milestone of 1,000 implants
Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of the 1,000th surgery with the Episealer® implant. Over 450 patients have had the implant for more than 2 years, and approximately 80 patients have passed 5 years since surgery. The majority are knee patients (Episealer® Knee), but the company is also executing on its early commercialization of the ankle implant, Episealer® Talus.
”I am very proud of the Episurf team today, and I would like to congratulate Prof. Ryd on this great achievement. Our history of strong clinical documentation and a solid operational experience creates a compelling combination for the future. We have satisfied customers, patients and counter-parties in a growing number of geographies, and we know that we are a market leader in a growing segment within orthopaedics,” says Pål Ryfors, CEO Episurf Medical.
"1,000 implants is a significant number. We are out of the cradle! As one of the founders of this endeavour, more than a decade ago, this is a cause for great satisfaction but also gratitude and relief. We can now say, for certain, that the Episurf technology delivers. The Episurf technology benefits hitherto unfulfilled needs. Finally, I would like to extend my gratitude to our shareholders for their support” says Prof. Leif Ryd, Senior Medical Advisor, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: